Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

What makes the elderly more susceptible to SARS-CoV-2 infection?

Why is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 (coronavirus disease 2019), biased towards infecting the aged population? A recently published study by Italian scientists linked aging, DNA damage, telomere shortening, and increased levels of angiotensin-converting enzyme 2 (ACE2) to this relationship.

13 Jun 2021

Role of traditional medicine against SARS-CoV-2

A group of researchers at Kannur University reviewed selected papers and in silico work on potential drug leads that could be used to manage COVID-19.

13 Jun 2021

Statins associated with reduced COVID-19 mortality and decreased need for ventilator support

Statins are medications widely used in the management of cardiovascular diseases and metabolic syndrome. Statins help lower serum lipids by blocking HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase), the rate-limiting enzyme of cholesterol biosynthesis.

11 Jun 2021

Cross-sectional study explores differences in biomarkers in fulminant and non-fulminant COVID-19 myocarditis

Researchers from the US recently conducted a study to examine the clinical course and echocardiographic and lab testing across clinically defined fulminant and non-fulminant COVID-19 myocarditis. This study is published on the preprint server, medRxiv.*

11 Jun 2021

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Researchers in the UK and Austria have identified a novel class of antibodies that is highly effective at neutralizing the original strain of severe acute respiratory syndrome (SARS-CoV-2) and maintaining blocking activity against certain viral variants that have emerged.

10 Jun 2021

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

A team of scientists in Estonia has recently evaluated the therapeutic/prophylactic efficacy of anti-SARS-CoV-2 polyclonal antibodies derived from the colostrum of immunized cows.

10 Jun 2021

DNA on-off switches for SARS-CoV-2 host receptor as potential therapeutic targets

Researchers in the United States and Canada have identified DNA on/off “switches” within the angiotensin-converting enzyme 2 (ACE2) gene that may control the expression of this host cell receptor before, during and after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

9 Jun 2021

Smoking and vaping increase ACE2 levels and virus spike binding in airway epithelium

A new bioRxiv preprint attempts to make some sense of why certain people experience more severe forms of COVID-19 as compared to others by pointing to the increase in virus binding that occurs in the presence of smoking or vaping.

9 Jun 2021

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

In a recently published article in the journal Frontiers in Immunology, scientists have reviewed the existing literature on antiviral and anti-inflammatory efficacy of resveratrol-based inhaled formulations in preventing SARS-CoV-2 infection and reducing COVID-19 severity.

9 Jun 2021

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers in the United States and the UK have conducted a study showing how the B.1.1.7 (Alpha) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adapted to suppress host innate immune responses in lung epithelial cells.

8 Jun 2021

Researchers identify a novel host-directed therapeutic approach to COVID-19

Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).

8 Jun 2021

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

People aren’t the only ones who should be social distancing — new research shows our cells need to as well. Researchers from Ohio State University in Columbus, Ohio, USA, used in-culture techniques to confirm SARS-CoV-2 transmission via cell-to-cell contact.

8 Jun 2021

What lessons have we learned over a year into the COVID-19 pandemic?

One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.

8 Jun 2021

What is the role of monoclonal antibody therapy in treating COVID-19?

A new study has been published in the journal Vaccines that deals with the present state of research on using mAbs for the treatment of the COVID-19 disease. Many clinical trials are being conducted to evaluate the efficacy and safety of several newly designed mAbs. Some of the mAbs are directed towards immune system responses, i.e., non-SARS-CoV-2 specific mAbs, while others are devised to neutralize the SARS-CoV-2 protein structure, i.e., SARS-CoV-2 specific mAbs.

8 Jun 2021

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

A new study has been published in the journal Vaccines that summarizes the history of vaccines, reviews the current progress in COVID-19 vaccine technology, and discusses the status of intranasal COVID-19 vaccines as a potential pathway to immunization.

8 Jun 2021

Wearable sensor shows link between blood pressure and intracranial pressure

Brazilian researchers have simultaneously demonstrated the mechanism linking high blood pressure to elevated intracranial pressure, validated a non-invasive intracranial pressure monitoring method, and proposed a treatment for high blood pressure that does not affect intracranial hypertension.

8 Jun 2021

NIH researchers identify novel small molecule inhibitors of SARS-CoV-2 variants

A team of scientists from the National Institutes of Health (NIH), USA, has recently identified six novel small molecule inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. The study is currently available on the bioRxiv* preprint server.

8 Jun 2021

Angiotensin News and Research

Further Reading

What makes the elderly more susceptible to SARS-CoV-2 infection?

Role of traditional medicine against SARS-CoV-2

Statins associated with reduced COVID-19 mortality and decreased need for ventilator support

Cross-sectional study explores differences in biomarkers in fulminant and non-fulminant COVID-19 myocarditis

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

DNA on-off switches for SARS-CoV-2 host receptor as potential therapeutic targets

Smoking and vaping increase ACE2 levels and virus spike binding in airway epithelium

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers identify a novel host-directed therapeutic approach to COVID-19

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

What lessons have we learned over a year into the COVID-19 pandemic?

What is the role of monoclonal antibody therapy in treating COVID-19?

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

Wearable sensor shows link between blood pressure and intracranial pressure

NIH researchers identify novel small molecule inhibitors of SARS-CoV-2 variants

Study reveals mechanisms by which SGLT2 inhibitors produce renoprotective effect

Distinct spike protein mutations in SARS-CoV-2 variant in Russia

Oral antidiabetic medication provides kidney protection in focal segmental glomerulosclerosis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News